CRISPR Therapeutics Proposes New Appointment to the Board of Directors
to its Board of Directors at the Company’s next annual general meeting to be held in 2024.
- to its Board of Directors at the Company’s next annual general meeting to be held in 2024.
- “I am honored to welcome Sandy to our Board during an important time in CRISPR Therapeutics’ continued evolution,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CRISPR Therapeutics.
- “Sandy brings a considerable breadth of experience to CRISPR Therapeutics gained from his senior roles at industry-leading companies and has a strong track record of success in finance, business development and corporate strategy.
- He has previously held board positions at a number of biopharma companies and currently holds a board position with Idorsia Pharmaceuticals Ltd.